Hemolysis qualitative analysis is an essential hemocompatibility study that evaluates whether blood-contacting medical devices cause red blood cell damage through visual and microscopic assessment. Performed in accordance with ISO 10993-4, ASTM F756, and GB/T 16886.4, this testing forms a core part of the biological safety evaluation required for regulatory submissions in major global markets. This article provides a comprehensive overview of qualitative hemolysis testing, covering applicable sample types, testing items, laboratory methods, acceptance criteria, and typical applications.
Technical Overview
Hemolysis is the rupture or disruption of red blood cell (erythrocyte) membranes, resulting in the release of hemoglobin into the surrounding plasma or test medium. When blood-contacting medical devices, biomaterials, or their extractable chemical constituents interact with circulating blood, they may induce hemolysis through mechanical shear forces, surface-mediated membrane damage, osmotic effects, or leachable-induced cytotoxicity. Clinically significant hemolysis can lead to anemia, hemoglobinuria, hyperkalemia, and renal injury, which makes hemolytic assessment an indispensable element of the biological evaluation of medical devices.
Hemolysis qualitative analysis focuses on identifying the presence, distribution, and morphological characteristics of red blood cell damage rather than calculating a numerical hemolysis percentage. The qualitative approach includes visual inspection of plasma or extract supernatant for hemoglobin coloration, optical microscopy of blood smears to detect erythrocyte shape changes, and classification of hemolysis severity. In practice, qualitative observations are commonly combined with quantitative assays, such as spectrophotometric measurement of the hemolysis index, to provide a complete hemocompatibility profile. Accredited third-party laboratories routinely perform these studies to support biological safety files for regulatory authorities worldwide.
The principal standards governing this testing include:
- ISO 10993-4: Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood
- ASTM F756: Standard Practice for Assessment of Hemolytic Properties of Materials
- GB/T 16886.4: Chinese national standard, technically equivalent to ISO 10993-4
- ISO 10993-12: Biological evaluation of medical devices - Part 12: Sample preparation and reference materials
Testing Samples
Externally Communicating Blood-Contact Devices
Intravascular catheters, guidewires, introducer sheaths, cannulae, infusion sets, transfusion sets, syringes, hypodermic needles, stopcocks, and luer connectors that communicate with the circulating blood stream, either transiently or for prolonged periods.
Circulating and Extracorporeal Devices
Hemodialyzers, hemoperfusion cartridges, oxygenators, cardiopulmonary bypass circuits, blood pumps, apheresis sets, extracorporeal tubing sets, and blood warmers, in which blood is processed outside the body and returned to the patient.
Implantable Blood-Contact Devices
Coronary and peripheral vascular stents, stent grafts, vascular grafts, prosthetic heart valves, vena cava filters, septal occluders, artificial vessels, and pacing leads intended for long-term contact with circulating blood.
Blood Collection and Storage Products
Blood collection bags, vacuum collection tubes, leukocyte depletion filters, and blood administration sets used in transfusion and blood banking applications.
Raw Materials, Coatings, and Process Changes
Polymer resins and films, metal coupons, ceramic samples, antithrombotic and hydrophilic coatings, adhesives, sterilization process residues, and 3D-printed materials under evaluation for new device development, supplier changes, or manufacturing modifications.
Testing Items
Typical qualitative and supporting endpoints included in a hemolysis qualitative analysis program are listed below:
- Visual hemolysis assessment: inspection of plasma or extract supernatant color after incubation and centrifugation, with comparison against negative and positive controls to detect free hemoglobin release.
- Erythrocyte morphology evaluation: preparation and microscopic examination of stained blood smears to identify echinocytes, spherocytes, schistocytes, ghost cells, and red cell agglutination or aggregation.
- Hemolysis severity grading: classification of observations as none, trace, slight, moderate, or severe based on defined visual and morphological criteria.
- Hemolysis index or hemolysis rate: quantitative companion assay using spectrophotometric determination of released hemoglobin, commonly measured at 540 nm with Drabkin's reagent.
- Plasma free hemoglobin and related hematology parameters: supplementary measurements such as red blood cell count, hematocrit, and total hemoglobin concentration.
- Extended hemocompatibility endpoints when required: thrombosis, coagulation assays, platelet count and activation, leukocyte count, and complement activation, as guided by ISO 10993-4.
Testing Methods
Sample Preparation
Samples are prepared in their final product configuration, including the sterilization method intended for commercial release. Test portions are cut, cleaned, or extracted in accordance with ISO 10993-12 using standardized surface-area-to-volume ratios and physiologically relevant extractants such as 0.9% sodium chloride injection. Extraction conditions are selected to simulate or appropriately exaggerate clinical use without degrading the material.
Direct Contact Method
Fresh anticoagulated blood, typically human or rabbit blood anticoagulated with sodium citrate or heparin, is placed in direct contact with the test sample or intact device. The mixture is incubated at 37 ± 1 °C for a defined period, commonly two to four hours, with gentle agitation. This method is suited to devices evaluated in their actual use configuration, such as catheter lumens or oxygenator fiber bundles.
Indirect Contact Extract Method
A material extract is first prepared under controlled conditions, for example 37 °C for 24 hours or 50 °C for 72 hours, and then incubated with diluted anticoagulated blood at 37 ± 1 °C, typically for three hours as described in ASTM F756. The extract method is appropriate for evaluating leachable substances and for materials that cannot be tested in intact form.
Qualitative Evaluation Procedure
- Centrifuge the incubated blood mixtures at the conclusion of the exposure period.
- Compare the supernatant color of the test groups against the negative control (clear to pale yellow) and the positive control (transparent red) to visually grade hemoglobin release.
- Prepare blood smears from the settled cells, fix and stain them using Wright or Giemsa staining, and examine erythrocyte morphology under an optical microscope.
- Record membrane integrity, cell shape, fragment frequency, ghost cell presence, and aggregation behavior, and assign a qualitative hemolysis grade.
Controls and Acceptance Criteria
Each study includes a negative control, commonly high-density polyethylene reference material or blood incubated without a sample, and a positive control, typically sterile purified water or a detergent solution that induces complete hemolysis. For qualitative analysis, a sample is considered acceptable when visual and microscopic findings are comparable to the negative control, with no meaningful supernatant coloration and no significant morphological alterations. When the qualitative study is paired with quantitative measurement, a hemolysis rate of five percent or less is generally accepted as non-hemolytic under ASTM F756, while results above this threshold trigger redesign, material substitution, or additional risk assessment.
Applications
Hemolysis qualitative analysis supports medical device manufacturers throughout the entire product lifecycle:
- Regulatory submissions: biological safety documentation for FDA 510(k) and PMA applications, CE technical files under the EU Medical Device Regulation, NMPA registration in China, and submissions in other jurisdictions.
- Design and development: comparative screening of candidate materials, coatings, and surface treatments to minimize blood damage early in the development cycle.
- Change control: demonstration of biological equivalence following material supplier changes, manufacturing process modifications, or sterilization method changes.
- Quality control: periodic or batch-based verification of hemocompatibility to confirm production consistency.
- Risk management: objective technical evidence supporting ISO 14971 risk analysis for blood-contacting hazards.
- Scientific and clinical research: hemocompatibility data generation for novel cardiovascular, dialysis, and extracorporeal technologies.
FAQ
What is the difference between qualitative and quantitative hemolysis testing?
Qualitative analysis determines whether hemolysis is present and describes its morphological characteristics through visual inspection of the supernatant and microscopic examination of red blood cells. Quantitative testing measures the concentration of hemoglobin released spectrophotometrically and calculates a hemolysis index or percentage. The two approaches are complementary and are frequently reported together in biological evaluation files.
When is hemolysis testing required for a medical device?
Under ISO 10993-4, hemocompatibility testing, including hemolysis assessment, is expected for devices that contact circulating blood. This includes externally communicating devices such as catheters and infusion sets, devices through which blood circulates externally such as dialyzers and oxygenators, and blood-contacting implants such as stents and heart valves.
Which standards govern hemolysis qualitative analysis?
The primary standards are ISO 10993-4 and its Chinese equivalent GB/T 16886.4 for the selection and conduct of blood interaction tests, ASTM F756 for the assessment of hemolytic properties of materials, and ISO 10993-12 for sample preparation and reference materials.
What blood source and anticoagulant are used?
Fresh human or animal blood is used, with rabbit blood being a common choice in accredited third-party laboratories. Blood is anticoagulated with sodium citrate or heparin, collected under controlled conditions, and used promptly within a defined window after collection to preserve erythrocyte integrity.
What results indicate an acceptable outcome?
In qualitative analysis, an acceptable sample shows no visible hemoglobin release relative to the negative control and no significant erythrocyte morphological changes under microscopy. In the associated quantitative assessment, a hemolysis rate of five percent or below is generally regarded as non-hemolytic.
How should manufacturers prepare samples for laboratory submission?
Manufacturers should provide devices or material samples in their final finished and sterilized condition whenever possible, together with product specifications, intended use and blood contact duration, device dimensions or surface area, and relevant material composition information to enable correct sample preparation under ISO 10993-12.